<DOC>
	<DOC>NCT00035269</DOC>
	<brief_summary>This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)</brief_summary>
	<brief_title>New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Community-Acquired Infections</mesh_term>
	<mesh_term>Pneumonia, Pneumococcal</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<criteria>Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Patients must have the signs and symptoms of pneumonia, with a chest xray showing a pneumonia. The patient must have S. pneumoniae (a specific bacteria) growing in sputum or blood to continue treatment. Patients cannot have taken more than one day of another antibiotic before entering this study. Patients with HIV and a low CD4 count are excluded.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Pharmacia</keyword>
</DOC>